TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18003652

Group type: EXPERIMENTAL
Intervention: 1995 Tobacco Control Act Amendment (TCAA)
Number of subjects: 73471

Group type: COMPARATOR
Intervention: Not applicable (control group: those not targeted by the TCAA)
Number of subjects: 73471
Study: 15661480

Group type: EXPERIMENTAL
Intervention: 200 g/d of avocado (30.6 g of fat)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (no avocado)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Both groups (experimental and control)
Number of subjects: 61
Study: 11836287

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg, twice a day)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 10452407

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (20 mg/d in a multivitamin syrup)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 65
Study: 7818153

Group type: EXPERIMENTAL
Intervention: Raised-leg exercises (20 minutes, three times a day)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Nonexercise (comparison group)
Number of subjects: 245
Study: 2100774

Group type: EXPERIMENTAL
Intervention: Eye films with apilac
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Eye films with apilac combined with low‐intensity helium‐neon laser radiation
Number of subjects: 47
Study: 106747

Group type: EXPERIMENTAL
Intervention: Flunisolide nasal spray 50 microgram q.i.d.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (propylene and polyethylene glycol vehicle)
Number of subjects: 20
Study: 30344071

Group type: EXPERIMENTAL
Intervention: Individual voice therapy
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Group voice therapy
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 77
Study: 31237119

Group type: EXPERIMENTAL
Intervention: Fenofibrate (250 mg/d)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 28376849

Group type: EXPERIMENTAL
Intervention: Study device (interactive cardiopulmonary resuscitation assist device with an automated external defibrillator)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Standard equipment
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Study device
Number of subjects: 106
Study: 25688781

Group type: EXPERIMENTAL
Intervention: Eliglustat (50 or 100 mg twice daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 23650172

Group type: EXPERIMENTAL
Intervention: Entecavir plus adefovir (EA)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Lamivudine plus adefovir (LA)
Number of subjects: 89
Study: 21249415

Group type: EXPERIMENTAL
Intervention: Azithromycin (AZM) given once daily for 3 days
Number of subjects: 157

Group type: COMPARATOR
Intervention: Cefcapene-pivoxyl (CFPN-PI) divided into three daily doses for 5 days
Number of subjects: 157
Study: 19271064

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 10 microg (D10)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 5 microg (D5)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control (normal saline, group N)
Number of subjects: 66
Study: 17006403

Group type: EXPERIMENTAL
Intervention: Posterior pericardiotomy (Group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No posterior pericardiotomy (Group B)
Number of subjects: 100
Study: 15301653

Group type: EXPERIMENTAL
Intervention: Monthly CBASP
Number of subjects: 82

Group type: COMPARATOR
Intervention: Assessment only
Number of subjects: 82
Study: 11702804

Group type: EXPERIMENTAL
Intervention: Priming dose of alcohol (0.55 g/kg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 9627768

Group type: EXPERIMENTAL
Intervention: Felodipine ER (2.5 mg)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Triamterene/HCTZ (25/12.5 mg)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Felodipine ER
Number of subjects: 216

Group type: COMPARATOR
Intervention: Triamterene/HCTZ
Number of subjects: 216
Study: 7837013

Group type: EXPERIMENTAL
Intervention: Botulinum neurotoxin A treatment to the ipsilateral antagonist medial rectus
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 47
Study: 3257843

Group type: EXPERIMENTAL
Intervention: Oral 25-hydroxyvitamin D 50 micrograms/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: No oral 25-hydroxyvitamin D
Number of subjects: 20
Study: 1593849

Group type: EXPERIMENTAL
Intervention: CCM-fortified orange juice (CCM-OJ)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Milk
Number of subjects: 12
Study: 321000

Group type: EXPERIMENTAL
Intervention: Oral ritodrine
Number of subjects: 38
Study: 30817784

Group type: EXPERIMENTAL
Intervention: Community Support Groups (CSGs) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 27571777

Group type: EXPERIMENTAL
Intervention: Coaching intervention (leaflets and three monthly coaching sessions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 25503598

Group type: EXPERIMENTAL
Intervention: 8% Capsaicin Patch (Qutenza)
Number of subjects: 6
Study: 23400375

Group type: EXPERIMENTAL
Intervention: Seminal plasma insemination (SP group)
Number of subjects: 346

Group type: COMPARATOR
Intervention: No seminal plasma insemination (noSP group)
Number of subjects: 346
Study: 21955570

Group type: EXPERIMENTAL
Intervention: Audiovisual message broadcast in waiting rooms for 6 months
Number of subjects: 20000

Group type: COMPARATOR
Intervention: No audiovisual message (control group)
Number of subjects: 20000
Study: 19248046

Group type: EXPERIMENTAL
Intervention: Vatalanib 1000 mg twice-a-day with imatinib (400 mg/day for stratum A, 500 mg twice-a-day for stratum B) and hydroxyurea (500 mg twice daily)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Imatinib and hydroxyurea
Number of subjects: 37

Group type: COMPARATOR
Intervention: EIAEDs
Number of subjects: 37
Study: 17443208

Group type: EXPERIMENTAL
Intervention: Amphetamine (5 mg initially, then 10 mg for 10 subsequent doses with 3- or 4-day separations)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Amphetamine
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 12874615

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg
Number of subjects: 682

Group type: COMPARATOR
Intervention: Losartan 50 mg/HCTZ 12.5 mg
Number of subjects: 682
Study: 10956399

Group type: EXPERIMENTAL
Intervention: Mailed invitation and reminder for Papanicolaou test
Number of subjects: 4802

Group type: COMPARATOR
Intervention: Control group (no invitation during follow-up)
Number of subjects: 4802

Group type: EXPERIMENTAL
Intervention: Total invited women (both groups)
Number of subjects: 4802

Group type: COMPARATOR
Intervention: Total invited women (control group)
Number of subjects: 4802

Group type: EXPERIMENTAL
Intervention: Intervention group vs Control group
Number of subjects: 4802
Study: 8851875

Group type: EXPERIMENTAL
Intervention: Bismuth citrate/amoxicillin combination therapy (BIAM tablet; 250 mg amoxicillin base and 120 mg bismuth)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Bismuth citrate monotherapy (BI tablet; 120 mg bismuth)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Bismuth citrate/amoxicillin combination therapy (BIAM)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Bismuth citrate monotherapy (BI)
Number of subjects: 70
Study: 1294976

Group type: EXPERIMENTAL
Intervention: Cefamandole 1.5 g given one hour before surgery, repeated twice eight hourly, and throughout the operation if it lasted more than three hours
Number of subjects: 2

Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Cefamandole 1.5 g
Number of subjects: 2
Study: 6202437

Group type: EXPERIMENTAL
Intervention: Programmed electrical stimulation identified group 1 (20 patients) where VT or ventricular fibrillation was induced.
Number of subjects: 73

Group type: COMPARATOR
Intervention: Prophylactic antiarrhythmic therapy assigned to group 2 (53 patients).
Number of subjects: 73
Study: 31451248

Group type: EXPERIMENTAL
Intervention: Propolis and melatonin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28240967

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg
Number of subjects: 846

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 846

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg and Placebo
Number of subjects: 846
Study: 26121131

Group type: EXPERIMENTAL
Intervention: Mate-search priming condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mate-guarding priming condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 23973555

Group type: EXPERIMENTAL
Intervention: Web 2.0 portal access
Number of subjects: 230

Group type: COMPARATOR
Intervention: Control group (no portal access)
Number of subjects: 230
Study: 21306612

Group type: EXPERIMENTAL
Intervention: Cognitive training integrated in a comprehensive psychosocial programme (OPUS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comprehensive psychosocial programme alone
Number of subjects: 0
Study: 19800445

Group type: EXPERIMENTAL
Intervention: MenCC primary immunization
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: MenCC secondary immunization
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Nonconjugated MenC polysaccharide secondary immunization
Number of subjects: 21
Study: 17067455

Group type: EXPERIMENTAL
Intervention: Aggressive periodontitis (AgP)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Chronic periodontitis (CP)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 194
Study: 15521668

Group type: EXPERIMENTAL
Intervention: Transcutaneous and intranasal electric stimulation of nasal muscles only (Group 1)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Biofeedback training and home exercise program of specific nasal movements (Group 2)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Surface and intranasal EMG biofeedback assisted specific strategies for nasal muscle education, home exercises and electric stimulation (Group 3)
Number of subjects: 34
Study: 11228351

Group type: EXPERIMENTAL
Intervention: Guilty knowledge test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dual modality attention task
Number of subjects: 0
Study: 9310003

Group type: COMPARATOR
Intervention: Positive end-expiratory pressure (PEEP) at 0 cm H2O (ZEEP)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: PEEP at 15 cm H2O
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: PEEP at 15 cm H2O in patients with LIP on P-VL curve
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: PEEP at 15 cm H2O in patients without LIP on P-VL curve
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: High levels of PEEP
Number of subjects: 13
Study: 8449203

Group type: EXPERIMENTAL
Intervention: Captopril (n=20)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo (n=20)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Conventional therapy (n=28)
Number of subjects: 68
Study: 3544935

Group type: EXPERIMENTAL
Intervention: Ketotifen (2 mg/day) for 12 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 16
Study: 30933616

Group type: EXPERIMENTAL
Intervention: Pitavastatin 1 mg
Number of subjects: 1053

Group type: EXPERIMENTAL
Intervention: Pitavastatin 4 mg
Number of subjects: 1053
Study: 28854728

Group type: EXPERIMENTAL
Intervention: Second dose of kisspeptin-54 (9.6 nmol/kg) administered 10 hours after the first dose.
Number of subjects: 62

Group type: COMPARATOR
Intervention: Single dose of kisspeptin-54 (9.6 nmol/kg) administered 36 hours prior to oocyte retrieval and followed by saline 10 hours later.
Number of subjects: 62
Study: 25965091

Group type: EXPERIMENTAL
Intervention: Dry sterile dressing
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Metallic silver dressing
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Ionic silver dressing
Number of subjects: 315
Study: 23252474

Group type: EXPERIMENTAL
Intervention: Reflexology
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Lay foot manipulation
Number of subjects: 385

Group type: COMPARATOR
Intervention: Conventional care control
Number of subjects: 385
Study: 21458989

Group type: EXPERIMENTAL
Intervention: Psycho-educational group intervention (two weekly 6-h sessions of psycho-education and eight weekly 2-h sessions of group psychotherapy)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Patients using anti-depressive medication (both intervention and control groups)
Number of subjects: 210
Study: 19231082

Group type: EXPERIMENTAL
Intervention: Local anaesthetic plus hypnosis
Number of subjects: 45

Group type: COMPARATOR
Intervention: Local anaesthetic
Number of subjects: 45

Group type: COMPARATOR
Intervention: Local anaesthetic plus attention
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Local anaesthetic plus hypnosis (for parents)
Number of subjects: 45
Study: 17046804

Group type: EXPERIMENTAL
Intervention: Combined Pelvic Floor Muscle Exercises (PFME) and support group
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 29
Study: 14964334

Group type: EXPERIMENTAL
Intervention: Pulsed radio frequency energy therapy (PRFE)
Number of subjects: 40

Group type: COMPARATOR
Intervention: PRFE placebo treatment (sham device)
Number of subjects: 40
Study: 11117242

Group type: EXPERIMENTAL
Intervention: Bicarbonate/lactate peritoneal dialysis solution (Bic/Lac)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Standard lactate-buffered peritoneal dialysis solution (Lac)
Number of subjects: 106
Study: 9393461

Group type: EXPERIMENTAL
Intervention: Parents' assessments of speech acceptability
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Teachers' assessments of speech acceptability
Number of subjects: 20

Group type: COMPARATOR
Intervention: Expert clinicians' assessments of speech acceptability
Number of subjects: 20

Group type: COMPARATOR
Intervention: Naive peer raters' assessments
Number of subjects: 20
Study: 7964828

Group type: EXPERIMENTAL
Intervention: Controlled-resistance, continuous lumbar drainage (CRCLD)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Shunting (ventriculoperitoneal or lumboperitoneal)
Number of subjects: 15
Study: 3111705

Group type: EXPERIMENTAL
Intervention: Oral etidronate disodium, 20 mg/kg/day
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Oral etidronate disodium
Number of subjects: 63
Study: 29254887

Group type: EXPERIMENTAL
Intervention: AZD8931 (40 mg twice a day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: AZD8931
Number of subjects: 32
Study: 28818560

Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch (mean ± SD of 10.46 ± 4.63 mg/24 h, n = 17)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo patch (n = 17)
Number of subjects: 34
Study: 26415296

Group type: EXPERIMENTAL
Intervention: Transient vascular bypass during carotid endarterectomy (CEE)
Number of subjects: 45

Group type: COMPARATOR
Intervention: No Bypass (Control group)
Number of subjects: 45
Study: 24016511

Group type: EXPERIMENTAL
Intervention: Physicians' ratings of HRQoL using Short Form-8
Number of subjects: 334

Group type: COMPARATOR
Intervention: Patients' self-ratings of HRQoL using Short Form-12
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Physical inactivity
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Major depressive disorder
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Sleeping disorder
Number of subjects: 334
Study: 21173686

Group type: EXPERIMENTAL
Intervention: Midline group (intra-articular injection of 20 ml normal saline)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lateral group (intra-articular injection of 20 ml normal saline)
Number of subjects: 40
Study: 18498614

Group type: EXPERIMENTAL
Intervention: 33% N,N‐diethyl‐3‐methylbenzamide (deet)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10% and 20% (1S, 2'S) 2‐methylpiperidinyl‐3‐cyclohexene‐1‐carboxamide (SS220)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10% and 20% 1‐methyl‐propyl‐2‐(hydroxyethyl)‐1‐piperidinecarboxylate (Bayrepel)
Number of subjects: 0
Study: 16540115

Group type: EXPERIMENTAL
Intervention: Postevent information provided by an interviewer with varying levels of assertiveness (Study 1)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Postevent information provided by a confederate with varying levels of assertiveness (Study 2)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Varying assertiveness in social influence
Number of subjects: 2
Study: 12692110

Group type: COMPARATOR
Intervention: Total fruit consumption in the placebo arm
Number of subjects: 14120

Group type: COMPARATOR
Intervention: Rosaceae fruit consumption in the placebo arm
Number of subjects: 14120

Group type: COMPARATOR
Intervention: Cruciferae vegetables consumption in the placebo arm
Number of subjects: 14120

Group type: EXPERIMENTAL
Intervention: Beta-carotene and retinyl palmitate supplementation
Number of subjects: 14120
Study: 10977118

Group type: EXPERIMENTAL
Intervention: Morphine plus bupivacaine (Group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Morphine alone (Group B)
Number of subjects: 60
Study: 7567007

Group type: EXPERIMENTAL
Intervention: Epidermal growth factor
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 2362952

Group type: EXPERIMENTAL
Intervention: Sulpiride 400 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sulpiride 800 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sulpiride 1200 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sulpiride (all dosages)
Number of subjects: 24
Study: 450367

Group type: EXPERIMENTAL
Intervention: Hysterectomy alone
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Preoperative uterine radium followed by hysterectomy
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Hysterectomy and postoperative vaginal radium
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Grade I lesions
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Grade II lesions
Number of subjects: 189
Study: 31418851

Group type: EXPERIMENTAL
Intervention: Hormonal treatment
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Stroke and infarct
Number of subjects: 377

Group type: COMPARATOR
Intervention: Proven etiology group (rest)
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Down syndrome infants
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Hormonal therapy in Down syndrome
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Combination therapy in Down syndrome
Number of subjects: 377
Study: 28887113

Group type: EXPERIMENTAL
Intervention: 4 mg/kg TCZ
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 8 mg/kg TCZ
Number of subjects: 37
Study: 25623410

Group type: EXPERIMENTAL
Intervention: Cognitive bias modification (CBM) intervention
Number of subjects: 214

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 214
Study: 24324365

Group type: EXPERIMENTAL
Intervention: Active Training (AT) group
Number of subjects: 448

Group type: COMPARATOR
Intervention: Passive Training (PT) group
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Both groups (AT and PT)
Number of subjects: 448
Study: 21546263

Group type: EXPERIMENTAL
Intervention: Distal tibiofibular joint manipulation
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Proximal tibiofibular joint manipulation
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 43
Study: 18340089

Group type: EXPERIMENTAL
Intervention: Community Lay Health Advocate (CLHA) intervention
Number of subjects: 83

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 83
Study: 16872504

Group type: EXPERIMENTAL
Intervention: Training + Feedback
Number of subjects: 429

Group type: COMPARATOR
Intervention: Feedback Only
Number of subjects: 429
Study: 12849880

Group type: EXPERIMENTAL
Intervention: Phenobarbital
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 59

Group type: COMPARATOR
Intervention: Both antiepileptic drugs
Number of subjects: 59
Study: 10853210

Group type: EXPERIMENTAL
Intervention: Blind intubation via the ILM using a straight, silicone tube
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intubation with a Macintosh laryngoscope using a straight silicone tube
Number of subjects: 150

Group type: COMPARATOR
Intervention: Intubation with a Macintosh laryngoscope using a polyvinyl chloride tube
Number of subjects: 150
Study: 9226732

Group type: EXPERIMENTAL
Intervention: 2 mg/70 kg butorphanol, IV, in ice-cold water (2 degrees C)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 10 mg/70 kg morphine, IV, in ice-cold water (2 degrees C)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 10 mg/70 kg morphine, IV, in warm water (37 degrees C)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 2 mg/70 kg butorphanol, IV, in warm water (37 degrees C)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Saline, IV, in both conditions
Number of subjects: 13
Study: 8499682

Group type: EXPERIMENTAL
Intervention: Plasmanate
Number of subjects: 450

Group type: COMPARATOR
Intervention: Maternal serum
Number of subjects: 450
Study: 3432172

Group type: EXPERIMENTAL
Intervention: salbutamol
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: fenoterol
Number of subjects: 8

Group type: COMPARATOR
Intervention: salbutamol and fenoterol
Number of subjects: 8
Study: 29294153

Group type: EXPERIMENTAL
Intervention: CCTA
Number of subjects: 1778

Group type: COMPARATOR
Intervention: 2015 BTS guidelines
Number of subjects: 1778

Group type: COMPARATOR
Intervention: 2017 Fleischner guidelines
Number of subjects: 1778
Study: 27302744

Group type: EXPERIMENTAL
Intervention: Operant Behavioural Treatment (OBT)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Treatment (CBT)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Whole-body infrared heat (IH)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Pain-free controls (CON)
Number of subjects: 115